Biotech | January 05, 2022
Biogen exercises option with Ionis for spinal muscular atrophy
Biogen paid Ionis a US $ 60 million one-time upfront payment
Biogen paid Ionis a US $ 60 million one-time upfront payment
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
